Arbutus Biopharma Corporation

NASDAQ:ABUS

Biotechnology

Healthcare
$4.07 +1.13%

+$0.05 today

Market cap
$623.90M
Beta
0.63
P/E (TTM)
5.4
EPS (TTM)
$0.83
52W Low $3.04High $5.10

Volume 2.44M

Average 1.76M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$39.64M

FY 2025 · Annual

Investing Cash Flow

$15.58M

FY 2025 · Annual

-32.1% YoY

Financing Cash Flow

$5.72M

FY 2025 · Annual

-89.0% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(76.25M)(69.46M)(72.85M)(69.92M)(33.5M)
Depreciation & Amortization1.75M1.43M1.4M1.38M363K
Deferred Income Tax(8.18M)0000
Stock-Based Compensation6.42M7.18M9.3M8.99M6.95M
Change in Working Capital930K29.24M(18.23M)(2.83M)(10.02M)
Accounts Receivables413K(453K)(424K)(633K)1.38M
Inventory(1.91M)0000
Accounts Payables1.91M5.22M00(2.11M)
Other Working Capital517K24.48M(17.81M)(2.2M)(9.29M)
Other Non-Cash Items7.79M(3.75M)(5.56M)(2.47M)(3.43M)
Operating Cash Flow(67.53M)(35.36M)(85.94M)(64.85M)(39.64M)
Capital Expenditures(809K)(512K)(1.01M)(182K)0
Acquisitions (Net)1.81M0000
Purchases of Investments(82.22M)(130.43M)(80.51M)(141.51M)12.87M
Sales of Investments70.35M56M132.27M164.64M155.28M
Other Investing Activities(1.81M)020K0(152.56M)
Investing Cash Flow(12.68M)(74.94M)50.77M22.95M15.58M
Debt Repayment00000
Common Stock Issued134.67M20.32M29.85M44.12M5.72M
Common Stock Repurchased00000
Dividends Paid(12.14M)0000
Other Financing Activities14.71M11.49M795K7.87M0
Financing Cash Flow137.24M31.81M30.65M52M5.72M
Effect of Forex Changes5K(22K)25K(49K)14K
Net Change in Cash57.03M(78.51M)(4.49M)10.05M(18.32M)
Free Cash Flow(68.34M)(35.87M)(86.94M)(65.03M)(39.64M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$33.5M
+ D&A$363.0K
+ Stock-Based Comp$7.0M
+ Deferred Tax$0
- Working Capital-$10.0M
- Other Non-Cash-$3.4M
= Operating Cash Flow-$39.6M
- Capex$0
= Free Cash Flow-$39.6M

Analysis

FY2025 free cash flow is -$39.6M. FCF conversion is 118.3% of net income. Operating cash flow was -$39.6M, with capex of $0. The largest bridge item is Working Capital at -$10.0M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 12, 2026
10-QQuarterly reportNov 10, 2026
8-KCurrent reportNov 10, 2026
SC 13G/ASC 13G/A filingOct 27, 2026
8-KCurrent reportOct 22, 2026

Does ABUS generate free cash flow?

Arbutus Biopharma Corporation (ABUS) generated -$39.64M of free cash flow in fiscal 2025.

How much operating cash flow does ABUS produce?

Operating cash flow was -$39.64M, before capital expenditures of $0.00.